Contraception Development Research Center Program (P50 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

 The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral/social science, including market research to test user acceptability, research projects that are responding and well-coordinated to the contraceptive product being developed.  The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): November 29, 2021  

RFA-HD-22-003 Expiration Date New Date November 30, 2021 per issuance of NOT-HD-20-044. (Original Expiration Date: March 31, 2021  )

Agency Website

Amount Description

Each Center should propose a budget that reflects the actual needs of the proposed projects and costs; the budget must not exceed $1.3 million per year in direct costs, excluding third party F&A. Future year amounts will depend on annual appropriations.

The scope of the proposed project should determine the project period. The maximum period of performance is 4 years.

    Funding Type





    Environmental & Life Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational
    Social Sciences

    External Deadline

    November 29, 2021